Health Care  |  Biotechnology
74.34 0.0 0.0%
Stock Price | May 19, 2022, 4 p.m.
Bid: 68.28
Ask: 89.3
Prev. Close: 74.34
52 Week Low: 61.91
52 Week High: 88.26
PE Ratio: 17.7
Dividend Yield: %

Company Summary

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Read more Read less

Recently Viewed Tickers